| [ Summary ] |
HematideTM is a novel, synthetic peptide-based EPO receptor agonist, with a sequence of amino acids which is completely unrelated to that of endogenous EPO or rHuEPO. The peptide component of HematideTM has a degree of bioactivity and stimulates the same receptor that binds endogenous EPO or rHuEPO. HematideTM specifically binds to EPO receptor, induces the activation of signal transduction pathways, and promotes proliferation and differentiation of cells of the erythroid lineage along with promoting formation of erythrocytes. HematideTM can be administered intravenously or subcutaneously and PEG moiety confers a long elimination half-life, which allows once every four week dosing. Since the amino acid sequence of HematideTM is not related to EPO, anti-erythropoietin antibodies do not cross-react with HematideTM, suggesting that this compound could be used for patients with antierythropoietin-antibody-mediated pure red-cell aplasia. Its effect in humans has been demonstrated. Therefore, HematideTM is anticipated to be a new therapeutic agent for treatment of renal anemia. |